Skip to main content

United States News All stories

Every story in this section, newest first — page 322 of 373.

Grafa
Health

AstraZeneca, Daiichi reach key EU milestone for Enhertu expansion

The European Medicines Agency (EMA) has officially commenced its review of ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab, a move that could soon establish the antibody-drug conjugate (ADC) as a primary treatment for HER2-positive metastatic breast cancer in the European Union.

Read more: AstraZeneca, Daiichi reach key EU milestone for Enhertu expansion